Jazz Pharmaceuticals PLC
1JAZZ
Company Profile
Business description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact
Waterloo Road
Fifth Floor, Waterloo Exchange
DublinD04 E5W7
IRLT: +353 16347800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,800
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.80 | 20.60 | -0.22% |
| CAC 40 | 7,707.90 | 4.00 | 0.05% |
| DAX 40 | 24,037.33 | 135.12 | 0.57% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,196.34 | 9.00 | 0.10% |
| HKSE | 25,617.42 | 539.80 | 2.15% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 42,188.79 | 529.68 | -1.24% |
| NZX 50 Index | 13,112.52 | 42.07 | 0.32% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,927.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,875.53 | 17.60 | 0.46% |